Customer & Revenue Durability

GRR

91.2%

+0.3pp QoQ

NRR

117%

−2pp QoQ

NRR−GRR Gap

25.8pp

+2.3pp ⚠

Avg Contract Duration

22.4mo

−1.8mo 🚩

Support Escalation Rate

9.3%

+2.1pp 🔴

% Recurring Revenue

78%

−1pp

Cohort LTV Index (Cumulative Revenue at Equivalent Lifecycle Stage)

Discount Depth Distribution (Current Quarter)

Revenue Quality Mix

GRR vs. NRR Trend with Gap Analysis (8Q)

Top 20 Accounts by ARR with Health Indicators

#	Account	ARR ($K)	Contract End	Escalations	Risk
1	Mayo Clinic	14,200	2026-Q2	3	Low
2	Pfizer	11,800	2025-Q1	7	Medium
3	Johnson & Johnson	9,400	2026-Q3	2	Low
4	Moderna	8,100	2026-Q1	4	Low
5	AstraZeneca	7,600	2025-Q4	9	Medium
6	Illumina	6,900	2026-Q2	1	Low
7	Genentech	6,200	2025-Q2	14	High
8	Novartis	5,800	2025-Q3	6	Medium

Customer Health Score Distribution

Enterprise GRR Trend

Mid-Market GRR Trend

SMB GRR Trend

Contract Duration vs. Expansion Attach Rate

Expansion Attach Rate by Product

Support Escalation Rate vs. Churn (Lagged 90 Days)